Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
10/02/2025 13:10
Feb 10 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX AND LILLY ENTER GLOBAL LICENSING AGREEMENT FOR MASH
AND
OTHER CARDIOMETABOLIC INDICATIONS
* OLIX PHARMACEUTICALS INC - COLLABORATION TO DEVELOP AND
COMMERCIALIZE OLX75016 FOR MASH AND CARDIOMETABOLIC INDICATIONS
* OLIX PHARMACEUTICALS INC - TO RECEIVE INITIAL PAYMENT FROM
LILLY
TO COMPLETE PHASE 1 TRIAL
Source text: ID:nBwkY77Ma
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment